tiprankstipranks
Tourmaline Bio (TRML)
NASDAQ:TRML
US Market

Tourmaline Bio (TRML) Financial Statements

199 Followers

Tourmaline Bio Financial Overview

Tourmaline Bio's market cap is currently ―. The company's EPS TTM is $-11.325; its P/E ratio is -2.02; and it has a dividend yield of 63.47%. Tourmaline Bio is scheduled to report earnings on March 19, 2024, and the estimated EPS forecast is $-0.71. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ 1.52M$ -6.92M$ -14.65M$ -23.66M$ -19.32M
EBITDA$ 3.89M$ -7.90M$ -15.76M$ -24.30M$ -19.76M
Net Income Common Stockholders$ 45.77M$ -13.93M$ -14.74M$ -44.57M$ 984.00K
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 202.95M$ 147.02M$ 152.25M$ 165.81M$ 181.28M
Total Assets$ 210.29M$ 151.06M$ 159.12M$ 172.61M$ 193.72M
Total Debt$ 415.00K$ 634.00K$ 1.03M$ 1.27M$ 2.88M
Net Debt$ -202.54M$ -146.39M$ -151.23M$ -164.54M$ -178.40M
Total Liabilities$ 5.25M$ 8.19M$ 10.69M$ 10.88M$ 13.66M
Stockholders Equity$ 205.04M$ 142.87M$ 148.43M$ 161.73M$ 180.06M
Cash Flow-
Free Cash Flow$ 10.86M$ -6.87M$ -14.90M$ -17.22M$ -14.14M
Operating Cash Flow$ 11.02M$ -7.52M$ -14.68M$ -16.90M$ -13.87M
Investing Cash Flow$ -88.42M$ 55.93M$ 8.92M$ 27.41M$ 9.01M
Financing Cash Flow$ 156.46M$ 74.00K$ 137.00K$ 46.00K$ 60.00K
Currency in USD

Tourmaline Bio Earnings and Revenue History

Tourmaline Bio Debt to Assets

Tourmaline Bio Cash Flow

Tourmaline Bio Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis